Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters

David A. Rhodes1, Hung-Chang Chen2, James C. Williamson3, Alfred Hill1, Jack Yuan1, Sam Smith1, Harriet Rhodes1, John Trowsdale1, Paul J. Lehner3, Thomas Herrmann4 and Matthias Eberl2,5

1Department of Pathology, University of Cambridge, Cambridge, United Kingdom, 2Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom, 3Cambridge Institute for Medical Research, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 4Institut für Virologie und Immunbiologie, Julius-Maximilians-Universität Würzburg, Würzburg, Germany, 5Systems Immunity Research Institute, Cardiff University, Cardiff, United Kingdom

Activation of human Vγ9/Vδ2 T cells by “phosphoantigens” (pAg), the microbial metabolite (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) and the endogenous isoprenoid intermediate isopentenyl pyrophosphate, requires expression of butyrophilin BTN3A molecules by presenting cells. However, the precise mechanism of activation of Vγ9/Vδ2 T cells by BTN3A molecules remains elusive. It is not clear what conformation of the three BTN3A isoforms transmits activation signals nor how externally delivered pAg accesses the cytosolic B30.2 domain of BTN3A1. To approach these problems, we studied two HLA haplo-identical HeLa cell lines, termed HeLa-L and HeLa-M, which showed marked differences in pAg-dependent stimulation of Vγ9/Vδ2 T cells. Levels of IFN-γ secretion by Vγ9/Vδ2 T cells were profoundly increased by pAg loading, or by binding of the pan-BTN3A specific agonist antibody CD277 20.1, in HeLa-M compared to HeLa-L cells. IL-2 production from a murine hybridoma T cell line expressing human Vγ9/Vδ2 T cell receptor (TCR) transgenes confirmed that the differential responsiveness to HeLa-L and HeLa-M was TCR dependent. By tissue typing, both HeLa lines were shown to be genetically identical and full-length transcripts of the three BTN3A isoforms were detected in equal abundance with no sequence variation. Expression of BTN3A and interacting molecules, such as periplakin or RhoB, did not account for the functional variation between HeLa-L and HeLa-M cells. Instead, the data implicate a checkpoint controlling BTN3A1 stability and protein trafficking, acting at an early time point in its maturation. In addition, plasma membrane profiling was used to identify proteins upregulated in HMB-PP-treated HeLa-M. ABCG2, a member of the ATP-binding cassette (ABC) transporter family was the most significant candidate, which crucially showed reduced expression in HeLa-L. Expression of a subset of ABC transporters, including ABCA1 and ABCG1, correlated with efficiency of T cell activation by cytokine secretion, although direct evidence of a functional role was not obtained by knockdown experiments. Our findings indicate a link between members of the ABC protein superfamily and the BTN3A-dependent activation of γδ T cells by endogenous and exogenous pAg.

Keywords: butyrophilins, T cells, phosphoantigens, mevalonate pathway, ABCG2, NRF2
INTRODUCTION

Gammadelta (γδ) T cells are a lineage of innate-like “unconventional” T lymphocytes with potent cytotoxic, pro-inflammatory, and regulatory properties. They express, as a defining feature, a T cell receptor (TCR) composed of a γ and δ chain heterodimer, both products of V(D)J recombination, which distinguishes them from conventional αβ T cells (1).

Although often restricted to distinct anatomical locations including skin and intestinal epithelium, both major sites of host interaction with the microbiota and of pathogen entry, the role of γδ T cells in tissue immune surveillance is not fully understood (2, 3). Butyrophilins (BTNs) appear to be pivotal in the role of γδ T cells in tissue immune surveillance is not fully understood (2, 3). Butyrophilins (BTNs) appear to be pivotal in the regulation of γδ T cell activation by regulation of BTN3A molecules in this process and to identify novel components. The data indicate that environmental exposure, such as treatment of cells with the cytotoxic anticancer drug doxorubicin (DOX), may influence γδ T cell activation by regulation of BTN3A protein stability or trafficking and expression of ATP-binding cassette (ABC) transporters via the KEAP1/NRF2 stress response pathway.

MATERIALS AND METHODS

Expression Constructs

Primer sequences are listed in Table S1 in Supplementary Material. DNA encoding specific shRNA oligos directed to BTN3A isoforms, periplakin, and ABCG2 were cloned into pHIREN/puro using BamHI/EcoRI as described previously (30). Virus particles were produced by co-transfection of 293T cells with pCMV8.91 (gag-pol) and pMDG (VSV-G env) plasmids. Supernatant was harvested after 48 h, filtered, and used to transduce HeLa cells. Clones were selected by puromycin (1 μg/ml) for 24 h. shRNA oligonucleotide sequence targeting all BTN3A isoforms was: shBTN3A.CGTTGTCAGATGGAAG. For re-expression, HeLa shRNABTN3A cells were co-transduced with lentivirus carrying variant BTN3A1 sequences. Green fluorescent protein (GFP) positive cells were sorted using BD FACSARia cell sorter.

Cell Lines and DNA Constructs

HeLa-M (a gift from Dick van den Boomen CIMR, Cambridge) and HeLa-L (from Will McEwan, MRC-LMB, Cambridge) cervical carcinoma cells were grown in standard tissue culture conditions using RPMI-1640 medium plus 10% FCS, penicillin/streptomycin (100 U/ml) and L-glutamine (2 mM). Cells were routinely checked for mycoplasma (MycoAlert Lonza LT07-218). HLA typing was performed by Addenbrooke’s Hospital Histocompatibility and Immunogenetics (Tissue Typing) laboratory. Human embryonic kidney 293T and bladder carcinoma EJ28 cells were also grown in supplemented RPMI-1640 medium. Human foreskin fibroblasts HFF-T and fetal lung MRC-5T, both immortalized by expression of hTERT, the catalytic subunit of human telomerase (a gift of Stephen Graham, Department of Pathology) were grown in supplemented DMEM medium.

Cells (1 × 10^6) growing in six-well plates were transfected with DNA expression constructs using Fugene (Promega). For RT-PCR, total RNA was prepared from cultured cells using RNAeasy mini (Qiagen) and Superscript III (Invitrogen) used to...
produce first strand cDNA. Amplification was carried out using 2× Biorad iQ SYBR Green qPCR Master Mix (Biorad). RT-PCR products were analyzed by gel electrophoresis and cloned using Zero-Blunt Topo (Invitrogen).

Killing assay was by propidium iodide (PI) dye exclusion in cells treated with doxorubicin DOX (Cell Signaling). Cells were harvested and stained in 100 µL PBS (2.5 µg/ml PI) for 5 min before washing and analysis by fluorescence microscopy using a fluorescein isothiocyanate (FITC) excitation filter. The number of PI-negative cells was counted and compared with untreated controls.


dilution for 24 and 48 h.

Two HeLa cervical epithelium carcinoma cell lines, HeLa-L and HeLa-M, show Marked Variation in Their ability to activate Vγ9/Vδ2 T cells via BTN3A

Various tumor-derived and primary epithelial cell lines were tested for their ability to respond to the aminobisphosphonate drug zoledronate and present the microbial compound HMB-PP to Vγ9/Vδ2 T cells (Figure S1A in Supplementary Material). Two HeLa cervical epithelium carcinoma cell lines, HeLa-L and HeLa-M, showed profound differences in their ability to elicit cytokine (Figure 1; Figure S1 in Supplementary Material). HeLa-M cells were far more potent than HeLa-L cells in stimulating release of IFN-γ (Figure 1A; Figure S1B in Supplementary Material) upon pretreatment with HMB-PP. Responses to zoledronate similarly differed between the two cell lines (data not shown). Responses to either HeLa cell line were abrogated by expression of a single shRNA targeting the three BTN3A isoforms (shRNA- A κBTN3A cells), confirming the importance of BTN3A in mediating


dilution for 24 and 48 h.

Immunoblot and Quantitative Mass Spectroscopy of Surface-Biotinylated Proteins

Cell lysates were prepared in buffer (50 mM Tris–Cl pH 7.5, 150 mM NaCl, 1% Triton-X, EDTA-free protease inhibitor, Roche) by incubation for 10 min at 4°C, then pre-clearing by centrifugation. For immune blots, cleared lysates were solubilized in SDS-PAGE buffer (5 min, 95°C) and separated in 10% SDS-PAGE gels (NextGel) then transferred to PVDF membrane. Antibodies were added directly to blocked membranes (5% Marvel/PBS 0.1% Tween 20) and incubated for 1 h with primary and HRP-conjugated secondary antibodies. Blots were visualized with ECL reagent (GEhealthcare) before exposure to X-ray film (Fuji). Monoclonal CD277 20.1 (LifeSpanBio), NRF2 (AF3925 R&D Systems), ABCG2 (ab108312) anti-calnexin (3811-100), and anti-GFP (SAB4301138) were used as well as 0.56 and B6 rabbit anti-B30.2 polyclonal sera at concentration between 0.5 and 1 µg/ml (30). Cell fractionation was carried out using Qproteome cell compartment kit (Qiagen).

For plasma membrane profiling (PMP), HeLa-M cells (5 × 10⁷) in large T175 flasks were either left untreated or treated with HMB-PP (10 nM for 10 h). Cells were washed (1× PBS) then biotinylation reagents added (30 min at 4°C). After quenching, cells were harvested by scraping and processed for immunoprecipitation, by lysis in 1% Tx-100 TBS pH 8 buffer with protease inhibitor (Complete EDTA free, Roche) and end-over-end rotation for 30 min at 4°C. After centrifugation (10,000 g for 10 min), Streptavidin agarose resin (Thermo Fisher) was added to supernatants, with incubation for 2 h at 4°C. Agarose beads were washed (20×) in lysis buffer, 20× in 0.5% SDS in PBS, 20× in 0.6 M urea/tributylammonium bicarbonate (TEAB) pH 8.5, 5× in TEAB pH 8.5 before digestion overnight with 0.5 µg trypsin in a final volume of 50 µl TEAB (31). Resulting peptides were analyzed by LC-MS/MS analysis using an Orbitrap Fusion instrument (Thermo Fisher) utilizing a 60-min gradient. Raw data were searched using Mascot from within Proteome Discoverer (Thermo Fisher) v2.0 against the Uniprot human reference proteome. Peptide identifications were controlled at 1% FDR using Mascot Percolator. Proteins were quantified in a label-free manner using the precursor ion quantifier node.

T Cell Assays

Ethical approval for working with blood samples from healthy donors was obtained from the South East Wales Local Ethics Committee (08/WSE04/17) and the Cambridge Local Ethics Committee (HBREC.2015.27). All volunteers provided written informed consent.

Vγ9/Vδ2 T cells were expanded from peripheral blood mononuclear cells of healthy donors with 1 µM zoledronate (Zometa; Novartis) and 50 U/ml IL-2 (Proleukin, Chiron) for 14 days and further enriched to purities >98% CD3+ Vγ9+ by negative selection using a modified human γδ T cell isolation kit that depletes B cells, CD56+ T cells, NK cells, dendritic cells, stem cells, granulocytes, and monocytes (Stem Cell Technologies). Unless otherwise stated, target HeLa cells were pretreated with 10 µM zoledronate or 10 nM HMB-PP, then washed extensively before coculture with γδ T cells at a ratio of 1:10 (10⁴ target: 10⁴ effector cells). The amount of IFN-γ secreted into the culture supernatant over 24 h was measured by ELISA (eBioscience). Mobilization of CD107a onto the cell surface over the first 5 h of coculture was determined using a PE-conjugated anti-CD107a antibody (H4A3; BD Biosciences) in the presence of monensin at a 1:2,000 dilution (GolgiStop). Cells were acquired on a FACS Canto II and analyzed with FlowJo. HeLa cells were also incubated with agonist CD277 20.1 monoclonal antibody (eBioscience) to induce activation independently of phosphoantigens.

The murine T-cell hybridoma 53/4t/mCD28 TCR MOP was used to test Vγ9/Vδ2 TCR mediated activation, as described (32). In these experiments, HeLa cells used as stimulators (10⁴) were seeded in 96-well flat bottom tissue culture plate, allowed to adhere for 1 day before addition of T cells in fresh culture medium. Production of mouse IL-2 in culture supernatants was tested with a commercial mouse IL-2 ELISA kit.

RESULTS

Two Haplo-Identical HeLa Cell Lines, HeLa-L and HeLa-M, Show Marked Variation in Their Ability to Activate Vγ9/Vδ2 T Cells via BTN3A

Various tumor-derived and primary epithelial cell lines were tested for their ability to respond to the aminobisphosphonate drug zoledronate and present the microbial compound HMB-PP to Vγ9/Vδ2 T cells (Figure S1A in Supplementary Material). Two HeLa cervical epithelium carcinoma cell lines, HeLa-L and HeLa-M, showed profound differences in their ability to elicit cytokine (Figure 1; Figure S1 in Supplementary Material). HeLa-M cells were far more potent than HeLa-L cells in stimulating release of IFN-γ (Figure 1A; Figure S1B in Supplementary Material) upon pretreatment with HMB-PP. Responses to zoledronate similarly differed between the two cell lines (data not shown). Responses to either HeLa cell line were abrogated by expression of a single shRNA targeting the three BTN3A isoforms (shRNA-A κBTN3A cells), confirming the importance of BTN3A in mediating
Vγ9/Vδ2 T cell responses to both HMB-PP and zoledronate (Figures 1A, B).

The differential responsiveness of Vγ9/Vδ2 T cells to HeLa-L and HeLa-M cells was replicated when using the pan-BTN3A specific agonist antibody CD277 20.1, which induces BTN3A-dependent activation of Vγ9/Vδ2 T cell activation in the absence of HMB-PP or zoledronate (Figure 1C). In addition, production of IL-2 from a murine T cell hybridoma expressing human Vγ9/Vδ2 transgenes showed a similar differential response to HMB-PP (Figure S1D in Supplementary Material).

In striking contrast to these findings of cytokine secretion as a functional read-out for T cell responses, surface mobilization of CD107a/LAMP1 did not differ between Vγ9/Vδ2 T cells responding to the two HeLa lines, upon HMB-PP or CD277 20.1 antibody pretreatment (Figure 1D), indicating differential signaling requirements for the induction of cytokine secretion versus CD107a mobilization.

Taken together, these experiments demonstrated that HeLa-M cells were more efficient at activating Vγ9/Vδ2 T cells via BTN3A than HeLa-L cells, with regard to the induction of cytokine expression but not CD107a mobilization. These cell lines, therefore, represent a useful experimental model to investigate the molecular mechanism underlying the specific Vγ9/Vδ2 T cell responses to endogenous and exogenous pAg.

**BTN3A Transcripts Are Identical in HeLa-L and HeLa-M**

In order to account for the functional differences between HeLa-L and HeLa-M cells, full-length BTN3A transcripts were amplified by RT-PCR from HeLa cDNA, cloned, and sequenced (Figure 2). As shown in Figure 2A, transcripts of all three BTN3A isoforms were expressed at comparable levels in both HeLa-L and HeLa-M, with no differences in splicing and all were targeted with equal efficiency by shRNA. No sequence variation or mutation was detected when six clones from each cell line for each BTN3A isoform were compared to consensus sequences (BTN3A1 NM_007048, BTN3A2 NM_007047, BTN3A3 NM_006994) (data not shown). Known synonymous SNPs common in sub-Saharan Africa, but rare in other populations, were identified in all BTN3A1 sequences (dbSNP rs3857550, rs2393650, and rs537072716), suggesting that both HeLa lines were homozygous for these polymorphisms. BTN3A2 and BTN3A3 nucleotide sequences showed no polymorphisms; however, allelic exclusion or haplotype bias in transcript expression was not assessed. By tissue typing of genomic DNA, both HeLa cell lines were HLA-A68-B15:03/15 -Bw6 -C12 -DR 01:02/01:26 haplo-identical. These data provided convincing authentication of the HeLa lines by conformation of their common genetic origin.

**Cellular Markers of Activation Are Unaffected**

Transcripts for BTN3A1 were shown to be induced by type I and type II interferons and HeLa-L and HeLa-M cells did not differ in this regard (Figure 2B and data not shown). By cytometry, there was comparable upregulation of surface MHC-I and MHC-II by IFN-γ treatment; however surface staining using CD277 20.1 antibody was not detected, indicating a discrepancy between transcriptional regulation and protein expression (Figure 2C).

In order to investigate the possibility of a soluble factor influencing T cell activation and also a more physiologically relevant stimulus potentially influencing BTN3A1 expression, we studied the response of both HeLa lines to treatment with supernatants collected from 24 h cocultures of Vγ9/Vδ2 T cells activated with HMB-PP (10 nM) loaded HeLa-M cells. Transcripts for a
number of activation markers, including MHC-II DMα, HLA-E, MHC-II trans-activator CIITA, and TRIM21 were analyzed by RT-PCR in addition to BTN3A1 (Figure 2D). Some variation in HeLa-derived transcripts was detected, particularly CXCL10 and IDO-1 and a slight increase in BTN3A1 transcripts upon activation in HeLa-M was not seen in HeLa-L. However, convincing BTN3A expression or activation at the cell surface was not detected by cytometry using CD277 20.1 antibody as for Figure 2C (data not shown). BTN2A1 transcripts did not vary between samples, and there was no correlation between butyrophilin BTN2A or BTN3A expression and CIITA/MHC-II in HeLa cells (6). A more detailed quantitative analysis of some transcripts, for example CXCL10 or IDO-1 may be warranted, but the data so far were not consistent with a major signaling defect in either HeLa line which could account for differential responses in T cell assays or with transcriptional control affecting BTN3A1 activation.

### No Variation in Expression of BTN3A1 Interactors

The cytoskeletal adaptor protein periplakin (PPL) and the RAS superfamily GTPase RhoB were recently identified as BTN3A1 interacting molecules (30, 33). We tested whether the differential BTN3A1-dependent responsiveness of Vγ9/Vδ2 T cells to HMB-PP loaded HeLa-L and HeLa-M might be due to variation in PPL and/or RhoB expression. In duplicated RT-PCR experiments, transcripts for PPL were slightly more abundant in HeLa-L compared to HeLa-M. By analyzing separate domains of the mRNA, no variation in splicing which conceivably could affect protein interactions or shRNA-mediated transcript suppression was detected (Figure 2E). In addition to PPL itself, we detected transcripts for the PPL interacting molecule PLEC1 (Figure 2E) but not for kazrin or envoplakin (34–36). RhoB transcripts were detected abundantly in both HeLa lines and were not obviously affected by activation with Vγ9/Vδ2 T cell supernatants. By western blot, major variation in PPL protein level was not detected between the HeLa cell lines either with, or without, activation using IFN-γ or using T cell supernatants (Figure 2F). Neither did we see any discrepancy in cellular distribution by cell fractionation; PPL was distributed equally in soluble, membrane, nuclear, and cytoskeletal/detergent resistant membrane fractions as shown previously (Figure 2G) (30).

These experiments suggested that differences in the expression of BTN3A1 interacting molecules did not account for the functional variation between HeLa-L and HeLa-M cells. By contrast, in a direct comparison in T cell assays of HeLa-L and HeLa-M PPL knockdown lines, produced by expression of three different PPL targeting shRNA (Figure S2 in Supplementary Material), wide variation in responses as measured by IFN-γ was detected. The PPL knockdown experiments were consistent with our initial conclusion of a regulatory rather than mandatory role for PPL in transmitting activation signals to T cells (30).

### Detection of BTN3A1 by Re-Expression in shRNA<sup>BTN3A</sup> Cells

Although mRNA transcripts were detectable, BTN3A proteins were not abundantly expressed in HeLa cells. In addition, CD277 20.1 antibody binding to HeLa cells was not convincing
by cytometry (Figure 2C), despite the fact that this agonistic antibody elicited potent \(V\gamma9/V\delta2\) T cell activation (Figure 1B). In order to overcome the limitations posed by low expression levels, we re-expressed BTN3A isoforms in wild-type and BTN3A knockout (shRNA\(^{BTN3A}\)) cells using a lentiviral vector which afforded an independent marker of transgene expression via detection of GFP (Figures 3A,B).

By transient transfection of either HeLa-L or HeLa-M with expression vectors for BTN3A1, BTN3A2, and BTN3A3, significant surface CD277 20.1 antibody staining was not detected for any of the three BTN3A isoforms, even with high GFP transgene expression (Figure S2A in Supplementary Material). In contrast, BTN3A2 and BTN3A3, but not BTN3A1, were productively expressed on the surface of 293T cells using the same transfection strategy, indicating that surface expression of BTN3A/CD277 was tightly regulated, by a mechanism which targeted BTN3A1 preferentially and which differed between cell lines.

By western blot analysis of lysates from transiently transfected cells, there was marked variation in the ability of CD277 20.1 antibody to detect the different BTN3A isoforms (Figure 3C; Figure S2B in Supplementary Material). While BTN3A1 was barely detectable, BTN3A2 was abundant (at levels expected from transgene expression) and BTN3A3 was expressed at intermediate levels. Authentic expression of full-length proteins was confirmed in some experiments using isoform specific antisera directed against the B30.2 domains of BTN3A1 and BTN3A3 (Figure 3C; Figure S2 in Supplementary Material), requiring extended exposure to X-ray film.

The above experiments indicated an intracellular checkpoint to BTN3A1 expression. To determine if this was mediated by protein degradation, we tested the effect of the proteasome inhibitor MG132 and bafA, an inhibitor of lysosome/autophagy pathways, on BTN3A1 expression in lentivirally transduced HeLa-L and HeLa-M shRNA\(^{BTN3A}\) cells (Figure 3D). By western blot using CD277 20.1 antibody, full-length soluble BTN3A1 (57 kDa) was detected in the untreated HeLa-M re-expression line, but was barely detectable in the HeLa-L lysate. Instead, a lower molecular weight band of 38 kDa was detected in HeLa-L samples, indicative of BTN3A1 protein cleavage. Alternatively, the 38-kDa protein could represent endogenous BTN3A2, although BTN3A2 was not detected abundantly in un-transfected cell lines (Figure S3 in Supplementary Material). Levels of detergent-soluble, full-length BTN3A1 were reduced by MG132 treatment, but were unaffected by bafA. In contrast, MG132 treatment of HeLa-L cells led to the appearance of full-length BTN3A1 (57 kDa) in the detergent resistant fractions from Tx-100 lysates, suggesting a potential redistribution of BTN3A1 in the membrane by proteasome inhibition.

Taken together, these results were consistent with a mechanism controlling surface expression of BTN3A protein isoforms, in particular BTN3A1, by protein production, stability, or trafficking.

### PMP of HMB-PP Treated Cells Identifies ABCG2

We next searched for differences in cellular factors that might influence pAg presentation in the two HeLa cell lines using surface biotinylation, followed by immunoprecipitation and quantitative mass spectroscopy (37). Bulk HeLa-M cells were allowed to adhere (10 h), then were either left untreated or treated with HMB-PP (10 nM for 10 h) prior to PMP as described (38).

By this approach, ABCG2 (also called breast cancer resistance protein) was identified as a candidate whose expression was significantly influenced by HMB-PP in HeLa-M cells (Figure 4A). ABCG2 is a member of the superfamily of ABC transporters and was originally characterized as a drug efflux pump (39). Variation in expression was modest (log2 = 2.69 increase), but several independent peptides of ABCG2 were detected. FAM129B, a molecule involved in RAS activation, was another candidate potentially affected by HMB-PP treatment (log2 = 2.15 increase) (40). By RT-PCR from the panel of untreated versus treated HeLa cDNA (Figure 4B), transcripts for
ABCG2 were reduced in HeLa-L compared to HeLa-M samples, an observation not seen for other candidates, while FAM129B transcripts did not vary (Figures 2C,D). Reduced expression of ABCG2 total protein in HeLa-L compared to HeLa-M cell lysate was confirmed by western blot (Figure 4C), but variation in expression by HMB-PP treatment was not and surface ABCG2 was not detected by flow cytometry. However, reduced levels of ABCG2 by MG132 treatment was seen (Figure 4C), similar to that detected for BTN3A1 (Figure 3D). Expression of NRF2 (nuclear factor erythroid 2-related factor 2), a basic leucine zipper (bZIP) protein and major transcriptional regulator of ABCG2, was stabilized in the MG132 treated samples as expected, with increased levels of NRF2 evident in HeLa-M versus HeLa-L samples, consistent with the higher expression of ABCG2 in these cells (Figure 4C).

From these data, ABCG2 was the most promising candidate to account for the differential effects of the HeLa cell lines in T cell assays, implicating this molecule in pAg presentation. Therefore, HeLa-M cells expressing shRNA targeting ABCG2 (shRNA<sub>ABCG2</sub>) were constructed. Reduced ABCG2 expression in shRNA<sub>ABCG2</sub> cells was confirmed by western blot (Figure 4C bottom panel) as was a functional effect in killing assays, by increased sensitivity to DOX, a major target substrate of ABCG2 (Figure 4D). However, in coculture assays with Vγ9/Vδ2 T cells, no effect on the efficiency of T cell activation of HMB-PP loaded HeLa-M shRNA<sub>ABCG2</sub> cells was detected, as measured by ELISA for IFN-γ (Figure 4E). With shRNA<sub>BTN3A1</sub> cells acting as control, a modest effect of shRNA<sub>BTN3A1</sub> cells was detected in these experiments, but no effect of shRNA<sub>RhoB</sub> or shRNA<sub>PLEC1</sub> cells. RhoB has been implicated previously in pAg presentation using similar shRNA-mediated knockdown (33), so the lack of specific effects in our experiments may be indicative of ineffective transcript suppression or variation between different cell lines. The mechanism by which TRIM21 may be affecting γδ T cell activation is unexplained (41).

Expression of a number of functionally related ABC transporters was examined by RT-PCR in the activated HeLa cell panel, including ABCB1 (multidrug resistance 1, MDR1), ABCG1 (white), ABCA1 (cholesterol export regulatory protein, CERP), ABCC1 (multi-resistance protein 1), and ABCC5 (multi-resistance protein 5). While expression of the latter two (ABCC1 and ABCC5) did not vary, transcripts for ABCB1, ABCG1, and ABCA1 did (Figure 4B). ABCB1 showed a pattern of expression similar to ABCG2, while ABCG1 and ABCA1 transcripts were only detected in treated samples of HeLa-L, and not in HeLa-M.

Taken together, the results revealed dysregulated expression of a subset of ABC transporters, which correlated with efficiency of γδ T cell activation, suggesting a link between these members of the ABC protein superfamily and pAg-dependent γδ T cell activation.

**Discussion**

Butyrophilin BTN3A proteins are the critical determinants of pAg presentation to Vγ9/Vδ2 T cells, but their precise role and how they are regulated is not fully understood. In order to address this issue and with a view to identifying novel effectors, we studied two HeLa cell lines which showed marked differences in their ability to activate Vγ9/Vδ2 T cells in response to pAg loading. Endogenous levels of all BTN3A isoforms were low in HeLa cells.
and were not detected by western blotting or flow cytometry. By PMP using quantitative mass spectroscopy in HeLa-M cells that were untreated or treated with HMB-PP, BTN3A1 and BTN3A2 isoforms were detected at low levels, with minor variation by treatment. Subsequent experiments using PMP may allow for interrogation of endogenous BTN3A proteins, their regulation by pAg and correlation with T cell activation in different presenting cells (42).

BTN3A1 protein stability at steady state, where BTN3A1 transgene re-expression was carefully controlled by GFP, was reduced significantly compared to that of the other isoforms, BTN3A2 and BTN3A3. We also detected differences in BTN3A1 protein between the two HeLa cell lines. The data are consistent with regulation of BTN3A1 at the level of protein stability. Protein truncation, presumably resulting from proteolytic cleavage to remove the B30.2 domain was also evident using anti-BTN3A antibodies. The possibility that posttranslational modification, for instance by N-linked glycosylation, may be influencing CD277 20.1 antibody recognition of BTN3A1 by affecting protein trafficking and stability cannot be ruled out. It is also unclear whether the free B30.2 domain, a potential degradation intermediate, has a separate function.

It is possible that specific miRNA or mRNA processing, resulting in a block or premature stop in translation could account for truncated and/or reduced protein levels, although no effect on BTN3A1 transcripts in re-expression lines was detected by RT-PCR. Since inhibitor MG132 did not give a clear picture of protein stabilization, as exemplified here by stabilization of NRF2, it is not clear whether BTN3A1 instability is due to proteasome function. Lysosomal inhibition also had no effect. Therefore, another mechanism of protein maturation and trafficking, acting at the level of protein translation or membrane insertion may be involved.

Control of BTN3A1 stability would provide a dynamic mechanism to control Vy9/V82 T cell activation, similar to that shown for the homologous molecule PD-L1 in controlling αβ T cell responses (43). The fact that BN3A1 expression appears to be limiting over BTN3A2 will also influence interactions between the two isoforms, proposed recently to be essential for Vy9/V82 T cell activation (11). Regulation of BTN3A1 stability would also offer a means to modulate immune-surveillance by Vy9/V82 T cells, representing a potential immune-evasion mechanism exploited by tumors and intracellular pathogens.

ABCG2 was identified as a potential candidate protein in pAg-dependent T cell activation using PMP of HMB-PP treated HeLa-M cells. ABCG2 correlates functionally with dye negative side population, a biomarker of cancer stem cells (44) and was considered an interesting functional candidate in pAg presentation because of the known association with statins, cholesterol metabolism, and the HMG-CoA reductase pathway (45, 46). However shRNA ABCG2 knockdown cells showed no functional defect in T cell assays. It is possible that shRNA did not reduce ABCG2 levels sufficiently in HeLa-M ABCG2 cells to influence this assay, or that other members of the ABC transporter family with similar expression and substrate profile (for example, ABCB1) compensated for its absence in these cells.

In addition to ABCG2 and ABCB1, transcription of ABCA1 and ABCG1 was dysregulated. ABCA1 and ABCG1 are also linked functionally to cholesterol metabolism, acting as regulators of cholesterol transport (47, 48). Since these molecules are not known to be induced by pro-inflammatory cytokines, it is unclear what signals from the γδ T cell supernatant, derived from cocultures with HeLa-M cells containing 10 nM HMB-PP, induced transcription of ABCA1 and ABCG1 in HeLa-L cells but not in HeLa-M. Published data describe a role in γδ T cell activation for ABCA1 acting together with BTN3A1 as a pAg efflux transporter in myeloid cells, linked to the LXR (liver X receptor) transcription factor (49). In the ABCA1 efflux model (49), ABCA1 drives IPP into the extracellular compartment to activate γδ T cells in trans. In our system, ABCA1 expression in activated HeLa-L cells would theoretically reduce intracellular HMB-PP concentration to thereby limit the pool available to activate BTN3A1. However, ABCA1 did not enhance T cell activation by HMB-PP-loaded HeLa-M because it did not appear to be expressed in these cells. Therefore, ABCA1 alone cannot account for the effects we detected, and it is also difficult to resolve an extracellular pAg delivery and sensing mechanism with the binding of pAg to the cytosolic B30.2 domain of BTN3A1 (9), unless this interaction promotes pAg export to bind BTN3A1 externally, as proposed by other workers (7, 50).

Conventional MHC restricted antigen presentation to TCR expressed on αβ T cells relies on peptide transport by the heterodimeric TAP1/2 transporter, and it is plausible that pAg transport similarly requires ABC family members. Other workers have investigated ABC5 (51) in addition to ABCA1 (49). Although most are described as drug or xenobiotic efflux pumps contributing to a multidrug resistance phenotype, endogenous substrates for many ABC transporters are largely uncharacterized. If these ABC transporters are involved, evidently there is more complexity in this system than current models of pAg presentation allow, in particular whether pAg transport is into or out of cells (or both) (50, 52) and whether they influence BTN3A expression by direct interaction (49). Further analysis of these ABC transporters seems warranted.

HeLa cells were the first cell line to be used for biomedical research, originating in the 1950s (53). HeLa-L and HeLa-M are two sublines the origins of which are obscure but which our data so far indicate are genetically identical. The cell lines were free of mycoplasma or other detectable infection and the chance observation of differences in pAg presentation and interaction with expanded Vy9/V82 T cells derived from different donors were stable for over 3 years with repeat samples acquired from original sources. The HeLa-M line historically showed elevated responses to IFN-γ (54) and in our hands showed resistance to the anticancer drug DOX in dye-exclusion killing assay, an effect reversed to some extent by ABCG2 knockdown. A feasible scenario, therefore, would be selection by an anticancer drug such as DOX resulting in DNA mutation (55), permanent activation of the KEAP1/NRF2 stress response pathway and increased ABCG2 expression in these cells (56). A similar approach was used to identify ABCG2 from a drug-resistant MCF-7 line (57).

Alternatively, signaling defects of the hedgehog pathway or LXR transcriptional regulation may be involved in ABC transporter expression (47, 58–60). If DOX impacts regulation of
BTN3A-dependent pAg sensing, then the use of such cytotoxic drugs in cancer treatment could impact immunotherapy strategies based on γδ T cells (23) by selecting clones with increased expression of survival factors which promote tumor growth. In any event, expression of this subset of ABC transporters may act as a biomarker for enhanced Vγ9/Vδ2 T cell activation by cytokine secretion, and it will be interesting to test this correlation in other cells and with other markers of activation. Current experiments are underway to identify a more comprehensive catalog of differences between HeLa-L and HeLa-M cells.

**AUTHOR CONTRIBUTIONS**

DR, ME, and TH designed research; DR, H-CC, and TH performed research; DR, ME, H-CC, and TH analyzed data; JT and PL provided capacity; DR and ME wrote the paper with input from all authors.

**ACKNOWLEDGMENTS**

This work was supported by MRC Project Grants MR/M020290/1 and MR/N023145/1, a Cardiff Incoming Visiting Fellowship (TH) and a Wilhelm Sander Stiftung Grant 2013.907.2. TH thanks L. Starick and A. Nöhren for excellent technical assistance.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00662/full#supplementary-material.

**REFERENCES**

1. Allison JP, Havran WL. The immunobiology of T cells with invariant gamma delta antigen receptors. *Annu Rev Immunol* (1994) 12:679–705. doi:10.1146/annurev.iy.09.040191.003335

2. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. *Immunity* (2009) 31:184–96. doi:10.1016/j.immuni.2009.08.006

3. Nielsen MM, Witherden DA, Havran WL. Gammadelta T cells in homeostasis and host defence of epithelial barrier tissues. *Nat Rev Immunol* (2017) 17:733–45. doi:10.1038/nri.2017.101

4. Di Marco Baros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, et al. Epithelia use butyrophilin-like molecules to shape organ-specific gamma-delta T cell compartment. *Cell* (2016) 167:203–18.e17. doi:10.1016/j.cell.2016.08.030

5. Henry J, Miller MM, Pontarotti P. Structure and evolution of the extended B7 class II genes. *Immunol Today* (2009) 30:285–8. doi:10.1016/S0167-5699(08)01418-2

6. Sarter K, Leimgruber E, Gobet F, Agrawal V, Dunand-Sauthier I, Barras E, et al. BTN3A-dependent pAg sensing, then the use of such cytotoxic drugs in cancer treatment could impact immunotherapy strategies based on γδ T cells. *J Immunol* (2015) 195:3215–25. doi:10.7414/jimmunol.1503710

7. Brandes M, Willimmann K, Moser B. Professional antigen-presentation function by human gammadelta T cells. *Science* (2005) 309:264–8. doi:10.1126/science.1110267

8. Decaup E, Duault C, Bezombes C, Poupot M, Savina A, Olive D, et al. Butyrophilin 3A1 binds phosphorylated antigens and stimulates human gammadelta T cells. *Nat Immunol* (2016) 17:733–45. doi:10.1038/jem.20150435

9. Hoffmann J, Mattusch T, Schöpf E, Duret D, Schäfer B, Wang J, et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress and malignancies. *Blood* (2003) 102:200–6. doi:10.1182/blood-2002-05-430470

10. Vantourout P, Laing A, Woodward MJ, Zlatareva I, Apolonio J, Lewis JM, et al. Heteromer interactions regulate butyrophilin (BTN) and BTN-like proteins governing γδ T cell biology. *Nat Commun* (2013) 4:1009. doi:10.1038/ncomms4780

11. Boyden LM, Lewis J, Barbee SD, Barbee SB, Bas A, Girardi M, Hayday AC, et al. Skint-1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epithelial gammadelta T cells. *Nat Genet* (2008) 40:656–62. doi:10.1038/ng.108

12. Barbee SD, Woodward MJ, Turchinovich G, Mention JJ, Lewis JM, Boyden LM, et al. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human gammadelta T cells in *Escherichia coli*. *FEBS Lett* (2001) 509:317–22. doi:10.1016/S0014-5793(01)03191-X

13. Brandes M, Willimmann K, Moser B, Etienne A, et al. Human Vgamma9/Vdelta2 T cells specifically recognize and kill acute myeloid leukemic blasts. *Blood* (2012) 120:5093–4. doi:10.1182/blood-2012-07-460378

14. Brandes M, Willimmann K, Moser B, Meinl E, Eberl M, et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. *Clin Exp Immunol* (2010) 161:290–7. doi:10.1111/j.1365-2249.2010.04167.x

15. Eberl M, Hintz M, Reichenberg A, Kollas AK, Wieser J, Jomaa H. Microbial isoprenoid biosynthesis and human gammadelta T cell activation. *FEBS Lett* (2003) 544:4–10. doi:10.1016/S0014-5793(03)00483-6

16. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells. *J Immunol* (2011) 187:1578–90. doi:10.4049/jimmunol.1002514

17. Fowler DW, Copier J, Daigleish AG, Bodman-Smith MD. Zoledronic acid renders human M1 and M2 macrophages susceptible to Vδ2(+)-gammadelta T cell cytotoxicity in a perforin-dependent manner. *Cancer Immunol Immunother* (2017) 66:1205–15. doi:10.1007/s00262-017-2111-1

18. Meraviglia S, Eberl M, Moser B. Professional antigen-presentation function by human gammadelta T cells. *Science* (2003) 309:264–8. doi:10.1126/science.1110267

19. Meraviglia S, Eberl M, Vermijlen D, Tardaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. *Clin Exp Immunol* (2010) 161:290–7. doi:10.1111/j.1365-2249.2010.04167.x

20. Tyler CJ, Doherty DG, Moser B, Eberl M. Human Vγ9/Vδ2 T cells: innate adaptors of the immune system. *Cell Immunol* (2015) 296:10–21. doi:10.1016/j.cellimm.2015.01.008

21. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. *Blood* (2003) 102:200–6. doi:10.1182/blood-2002-12-3665

22. Meraviglia S, Eberl M, Vermijlen D, Tardaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vγ9Vδ2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. *Clin Exp Immunol* (2010) 161:290–7. doi:10.1111/j.1365-2249.2010.04167.x

23. Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, et al. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. *J Immunol* (2012) 188:4701–8. doi:10.4049/jimmunol.1103710

24. Hannani D, Ma Y, Yamazaki T, Dechanet-Merville J, Kroemer G, Zitvogel L. Harnessing gammadelta T cells in anticancer immunotherapy. *Trends Immunol* (2012) 33:199–206. doi:10.1016/jjit.2012.01.006

25. Moser B. Tumor-killing gammadelta-TCRs take center stage. *Blood* (2012) 120:5093–4. doi:10.1182/blood-2012-10-460378

26. Khan MW, Eberl M, Moser B. Potential use of gammadelta T cell-based vaccines in cancer immunotherapy. *Front Immunol* (2014) 5:512. doi:10.3389/fimmu.2014.00512

27. McCarthy NE, Hedin CR, Sanders TJ, Ammon P, Hoti I, Ayada I, et al. Azathioprine therapy selectively ablates human Vδ2(+) T cells in Crohn's disease. *J Clin Invest* (2015) 125:3215–25. doi:10.1172/JCI80840
28. Papotto PH, Reinhardt A, Prinz I, Silva-Santos B. Innately versatile: gamma-delta T cells in inflammatory and autoimmune diseases. *J Autoimmun* (2018) 87:26–37. doi:10.1016/j.jaut.2017.11.006

29. Benyamine A, Le Roy A, Mamesset E, Gertner-Dardenne J, Castanier C, Orlanducci E, et al. BT3N3A molecules considerably improve Vgama9Vdelta2T cells-based immunotherapy in acute myeloid leukemia. *Oncoimmunology* (2016) 5:e1146834. doi:10.2147/onci.2016.1146834

30. Rhodes DA, Chen HC, Price AJ, Keeble AH, Davey MS, James LC, et al. Activation of human gammadelta T cells by cytosolic interactions of BT3N3A1 with soluble phosphoantigens and the cytoksetal adaptor periplakin. *J Immunol* (2015) 194:2390–8. doi:10.4049/jimmunol.1401064

31. Weekes MP, Tomasec P, Huttlun EL, Fielding CA, Nusinow D, Stanton RJ, et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. *Cell* (2014) 157:1460–72. doi:10.1016/j.cell.2014.04.028

32. Starick L, Riano E, Karunakaran MM, Kunzmann V, Li J, Kreiss M, et al. Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vgama9Vdelta2 TCR clonotypes and interferes with phosphoantigen activation. *Eur J Immunol* (2017) 47:982–92. doi:10.1002/eji.201646818

33. Sebestyen Z, Schepfer W, Vyorova A, Gu S, Rychnakova Z, Schiffer M, et al. RhoB mediates phosphoantigen recognition by Vgama9Vdelta2 T cell receptor. *Cell Rep* (2016) 15:1973–85. doi:10.1016/j.celrep.2016.04.081

34. Grooth KR, Sevilla LM, Nishi K, DiColandrea T, Watt FM. Kazrin, a novel perinerv-acting protein associated with desmosomes and the keratinocyte plasma membrane. *J Cell Biol* (2004) 166:653–9. doi:10.1083/jcb.200312123

35. Boczonadi V, McInroy L, Maatta A. Cytolinker cross-talk: periplakin composition and TLR signaling. *J Cell Biol* (2015) 209:113:644–9. doi:10.1073/pnas.1517112113

36. Sevilla LM, Nachat R, Klement JF, Uitto J, Djian P, et al. Activation of human gammadelta T cells by cytosolic interactions of BTN3A1. *J Autoimmun* (2017) 87:26–37. doi:10.1016/j.jaut.2017.11.006

37. Weekes MP, Antrobus R, Lill JR, Duncan LM, Hor S, Lehner PJ. Comparative analysis of techniques to purify plasma membrane proteins. *J Biomol Tech* (2010) 21:108–15.

38. Weekes MP, Tan SY, Poole E, Talbot S, Antrobus R, Smith DL, et al. Latency-associated degradation of the MRPI drug transporter during latent human cytomegalovirus infection. *Science* (2013) 340:199–202. doi:10.1126/science.1235047

39. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem and is a molecular determinant of the side-population phenotype. *Trends Biochem Sci* (2009) 34:176–88.

40. Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, et al. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. *Clin Pharmacol Ther* (2010) 87:558–62. doi:10.1038/clpt.2009.232

41. Hu M, To KK, Mak VW, Tomlinson B. The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. *Expert Opin Drug Metab Toxicol* (2011) 7:49–62. doi:10.1517/17425255.2011.538383

42. Kaneko T, Kanno C, Ichikawa-Tomikawa N, Kashiwagi K, Yaginuma A, Okoshi C, et al. Liver X receptor reduces proliferation of human oral cancer cells by promoting cholesterol efflux via up-regulation of ABCA1 expression. *Oncotarget* (2015) 6:33345–57. doi:10.18632/oncotarget.5428

43. Qian H, Zhao X, Cao P, Lei J, Yan N, Gong X. Structure of the human lipid exporter ABCA1. *Cell* (2017) 169:1228–39.e10. doi:10.1016/j.cell.2017.05.020

44. Castella B, Kopecka J, Sciancalepore P, Mandili G, Foglietta M, Nitro R, et al. The ATP-binding cassette transporter A1 regulates phosphoantigen release and Vgama9Vdelta2T cell activation by dendritic cells. *Nat Commun* (2017) 8:15663. doi:10.1038/ncomms15663

45. De Liberio G, Lau SY, Mori L. Phosphoantigen presentation to TCR gammadelta cells, a conundrum getting less gray zones. *Front Immunol* (2014) 5:679. doi:10.3389/fimmu.2014.00679

46. Kistowska M. Antigen Recognition and Thymic Maturation of Human TCR Vgamma9-Vdelta2 Cells. Ph.D. thesis, Basel: Universität Basel (2007).

47. Gu S, Nawrocka W, Adams EJ. Sensing of pyrophosphate metabolites by Vgama9Vdelta2 T cells. *Front Immunol* (2014) 5:688. doi:10.3389/fimmu.2014.00688

48. Adey A, Burton IN, Kitzman JO, Hiatt JB, Lewis AP, Martin BK, et al. The haptoglobin-resolyte pathway and epigenome of the aneuploid HeLa cancer cell line. *Nature* (2013) 500:207–11. doi:10.1038/nature12064

49. Tiwari RK, Kusari J, Sen GC. Functional equivalents of interferon-mediated signals needed for induction of an mRNA can be generated by double-stranded RNA and growth factors. *EMBO J* (1987) 6:373–87.

50. Calcagno AM, Foster JM, To KK, Salcido CD, Martin SE, Chewning KJ, et al. Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes. *Br J Cancer* (2008) 98:1515–24. doi:10.1038/sj.bjc.6604334

51. Hayes JD, McMahon M. NFR2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. *Trends Biochem Sci* (2009) 34:176–88. doi:10.1016/j.tibs.2008.12.008

52. Doyle L, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). *Oncogene* (2003) 22:7340–58. doi:10.1038/sj.onc.1206938

53. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. *Oncogene* (2011) 30:4874–86. doi:10.1038/onc.2011.195

54. Chen Y, Bieker MM, Teng NN. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer. *Mol Cancer* (2014) 13:625–34. doi:10.1002/mcan.20113

55. Ito A, Hong C, Rong X, Zhu X, Tarling EJ, Hedde PN, et al. Functional redundancy of an adaptive response in cancer. *ELIFE* (2015) 4:e08009. doi:10.7554/eLife.08009

Conflict of Interest Statement: The authors are not aware of any financial holdings or other personal or professional relationships which could be construed as affecting the objectivity of this manuscript.

The handling Editor declared a past co-authorship with one of the authors (ME).